Skip to main content

Table 1 TTS patients’ characteristics: Entire cohort and subdivision according to previous diagnosis of A/Ca. Statistical comparisons are between A/Ca and no A/Ca subgroups

From: Antecedent cancer in Takotsubo syndrome predicts both cardiovascular and long-term mortality

 Entire group (n = 346)A/Ca (n = 58)No A/Ca (n = 288)p
Duration of follow-up (years)4.1 (2.2–6.4)3.5 (1.2–5.8)4.4 (2.3–6.8)0.05
Age (years)69 ± 1374 ± 1068 ± 140.001
Male: (%)8.214.37.0NS
Secondary TTS (%)3447310.02
Site (Apex; %)66.464.366.7NS
Annual recurrence rate (%)2.11.82.2NS
CVS risk factors
 Hypertension (%)56.054.757.2NS
 Diabetes mellitus (%)18.21718.4NS
 Dyslipidemia (%)37.834.038.6NS
 Current smoking (%)9.89.49.9NS
Markers: size of acute attacks
 Minimal systolic BP (mmHg)97 ± 1698 ± 1596 ± 16NS
 Acute LVEF (%)46 ± 1244 ± 1347 ± 12NS
 Peak NT-proBNP (ng/L)4800 (2600–9000)5800 (3600–10,800)4600 (2500–8600)0.04
 Peak normetanephrine (pmol/L)980 (610–1400)960 (600–1460)980 (620–1410)NS
 Peak metanephrine (pmol/L)200 (200–270)210 (200–290)200 (200–270)NS
 Peak hs-CRP (mg/L)13 (6–44)23 (8–100)11 (6–38)0.01
 Peak troponin T (ng/L)400 (223–620)310 (187–564)400 (230–638)NS
In-hospital complications (%)
 Arrhythmias15.121.813.8NS
 Shock7.412.76.4NS
 Mortality3.28.92.10.02
 MACE20.330.918.20.04
Neoplasia (%)
 A/Ca (Prior/current)16.8   
 Chemo/Immunotherapy 34.6  
 Subsequent neo malignancy 6.9  
Discharge CVS medications (%)
 ACEi/ARB78.488.276.50.07
 βBl42.631.344.70.09
 Statins50.545.151.5NS
 Aspirin42.437.343.4NS